Researchers at the Institute for Health Research and Innovation (i3S) at the University of Porto participated in a study that found a protein that could be used to predict the effectiveness of chemotherapy in patients with triple-negative breast cancer.
The University of Porto Institute reveals in a statement that a study published in Cell Reports opens ‘doors to smarter use of chemotherapy’, although not ‘effective’ for all women with breast canceris the most widely used method.
In addition to side effects such as fatigue, anemia, nausea, and hair loss, “in about half of the cases, chemotherapy doesn’t even help,” stresses i3S, adding that a team of researchers that included Sandra Tavares tried to understand the reasons for treatment success or failure.
As a result, the researchers found a protein in tumor cells called FER that makes it possible to predict the effectiveness of chemotherapy in patients with this type of cancer.
Quoted in the statement, Sandra Tavares points out that women with triple-negative breast cancer and high levels of FERs “respond better to chemotherapy with taxanes, a drug usually associated with slowing down cell division and thus tumor growth.” .
“When [as pacientes] lack of this protein chemotherapy has no effect“, emphasizes a researcher in the” Cytoskeletal Regulation & Cancer “group at i3S.
Researchers are currently working to develop a test to assess protein levels in triple-negative breast tumors.
Patrick Derksen, a researcher at the Utrecht University Medical Center in the Netherlands who also led the study, also quoted the opinion as saying that The goal is to “use the test from the time of diagnosis” to enable “more individualized treatment”.
In addition to the test, the mechanism revealed in the study is “very important to clinicians and patients” because it explains the difference in responses to taxane chemotherapy.